# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst David Westenberg reiterates Elanco Animal Health (NYSE:ELAN) with a Neutral and raises the price targe...
Barclays analyst Balaji Prasad maintains Elanco Animal Health (NYSE:ELAN) with a Overweight and raises the price target from...
Elanco Animal Health (NYSE: ELAN) reports Q1 results: adjusted EPS $0.34 (-26% Y/Y), sales $1.21B (-4% Y/Y). 2024 guidance: EPS...